Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
出版年份 2016 全文链接
标题
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 18, Issue 6, Pages 590-597
出版商
Wiley
发表日期
2016-03-03
DOI
10.1111/dom.12654
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade
- (2015) Michael A. Weber et al. BLOOD PRESSURE
- The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers
- (2015) Bauke Schievink et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
- (2015) C David Sjöström et al. Diabetes & Vascular Disease Research
- Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
- (2015) Bauke Schievink et al. European Journal of Preventive Cardiology
- The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
- (2015) Dick de Zeeuw et al. Lancet Diabetes & Endocrinology
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
- (2014) H. J. Lambers Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
- (2014) D. de Zeeuw et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
- (2013) Richard E. Gilbert KIDNEY INTERNATIONAL
- Telmisartan Attenuates Diabetic Nephropathy by Suppressing Oxidative Stress in db/db Mice
- (2013) Chikage Sato-Horiguchi et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Effects of Dapagliflozin on Cardiovascular Risk Factors
- (2013) Agata Ptaszynska et al. POSTGRADUATE MEDICINE
- Sodium glucose cotransporter 2 and the diabetic kidney
- (2012) Muralikrishna Gangadharan Komala et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
- (2008) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started